The therapeutic community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 receptor that’s exhibiting significant efficacy in clinical trials for managing obesity. Unlike some existing weight loss solutions, retatrutide appears to provide a greater substantial redu